These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 31068271)

  • 1. Bictegravir and dolutegravir: head to head at 96 weeks.
    Barber TJ
    Lancet HIV; 2019 Jun; 6(6):e342-e343. PubMed ID: 31068271
    [No Abstract]   [Full Text] [Related]  

  • 2. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
    Orkin C; DeJesus E; Sax PE; Arribas JR; Gupta SK; Martorell C; Stephens JL; Stellbrink HJ; Wohl D; Maggiolo F; Thompson MA; Podzamczer D; Hagins D; Flamm JA; Brinson C; Clarke A; Huang H; Acosta R; Brainard DM; Collins SE; Martin H; ;
    Lancet HIV; 2020 Jun; 7(6):e389-e400. PubMed ID: 32504574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
    Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
    Sax PE; DeJesus E; Crofoot G; Ward D; Benson P; Dretler R; Mills A; Brinson C; Peloquin J; Wei X; White K; Cheng A; Martin H; Quirk E
    Lancet HIV; 2017 Apr; 4(4):e154-e160. PubMed ID: 28219610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
    Sax PE; Pozniak A; Montes ML; Koenig E; DeJesus E; Stellbrink HJ; Antinori A; Workowski K; Slim J; Reynes J; Garner W; Custodio J; White K; SenGupta D; Cheng A; Quirk E
    Lancet; 2017 Nov; 390(10107):2073-2082. PubMed ID: 28867499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
    Stellbrink HJ; Arribas JR; Stephens JL; Albrecht H; Sax PE; Maggiolo F; Creticos C; Martorell CT; Wei X; Acosta R; Collins SE; Brainard D; Martin H
    Lancet HIV; 2019 Jun; 6(6):e364-e372. PubMed ID: 31068272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir.
    Calza L; Borderi M; Colangeli V; Miani T; Nuti B; Bon I; Lazzarotto T; Viale P
    AIDS; 2022 Jan; 36(1):153-155. PubMed ID: 34873095
    [No Abstract]   [Full Text] [Related]  

  • 8. Weighing considerations with newer antiretrovirals.
    Venter WDF; Hill A
    Lancet HIV; 2020 Jun; 7(6):e374-e375. PubMed ID: 32504568
    [No Abstract]   [Full Text] [Related]  

  • 9. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
    Acosta RK; Willkom M; Andreatta K; Liu H; Martin R; Parvangada A; Martin H; Collins S; White KL
    J Acquir Immune Defic Syndr; 2020 Nov; 85(3):363-371. PubMed ID: 32701823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.
    Eron J; Hung CC; Baril JG; Slim J; Falcó V; Bogner J; Maggiolo F; Mills A; Sievers J; Man CY; Urbaityte R; Underwood M; Tenorio AR; Pappa KA; Wynne B; Koteff J; Gartland M; Smith KY; Aboud M
    J Acquir Immune Defic Syndr; 2020 May; 84(1):60-65. PubMed ID: 31977595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
    Deeks ED
    Drugs; 2018 Nov; 78(17):1817-1828. PubMed ID: 30460547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cases of coronavirus disease-2019 in HIV-infected transgender women.
    Adachi E; Saito M; Ikeuchi K; Hoshina T; Yotsuyanagi H
    AIDS; 2020 Jul; 34(9):1435-1436. PubMed ID: 32590441
    [No Abstract]   [Full Text] [Related]  

  • 13. Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice.
    Baldin G; Ciccullo A; Lombardi F; D'Angelillo A; Dusina A; Emiliozzi A; Farinacci D; Moschese D; Picarelli C; Borghetti A; Di Giambenedetto S
    AIDS Res Hum Retroviruses; 2021 Jun; 37(6):429-432. PubMed ID: 33280486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of Dolutegravir and Bictegravir Plasma Protein Binding: a First Approach for the Study of Pharmacologic Sanctuaries.
    Gelé T; Gouget H; Furlan V; Becker PH; Taburet AM; Lambotte O; Barrail-Tran A
    Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32868324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bictegravir.
    Spagnuolo V; Castagna A; Lazzarin A
    Curr Opin HIV AIDS; 2018 Jul; 13(4):326-333. PubMed ID: 29746268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks.
    Acosta RK; Willkom M; Martin R; Chang S; Wei X; Garner W; Lutz J; Majeed S; SenGupta D; Martin H; Quirk E; White KL
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30803969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
    Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients.
    Jary A; Marcelin AG; Charpentier C; Wirden M; Lê MP; Peytavin G; Descamps D; Calvez V
    J Antimicrob Chemother; 2020 May; 75(5):1290-1293. PubMed ID: 32065630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute pancreatitis associated with dolutegravir and lamivudine/abacavir administration.
    Thompson AB; Wynn BA; O Akerele D; A Rostad C; Anderson EJ; Camacho-Gonzalez AF; Spearman P; Chakraborty R
    AIDS; 2015 Jan; 29(3):390-2. PubMed ID: 25686687
    [No Abstract]   [Full Text] [Related]  

  • 20. Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy.
    Taiwo BO; Quiñones-Mateu ME; Smith K; Zheng L; Gulick R; Nyaku AN; Sax PE; Ha B; Kumwenda J; Olefsky M; Godfrey C; Wallis C
    AIDS Res Hum Retroviruses; 2020 Apr; 36(4):254-255. PubMed ID: 31914799
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.